Symptom management in patients with multiple sclerosis

      This paper is only available as a PDF. To read, Please Download here.


      Multiple sclerosis is a complex disease associated with a wide variety of different symptoms that can affect the ability of multiple sclerosis patients to carry out normal activities of daily living. Although a myriad of symptoms can afflict these patients, the most commonly reported include fatigue, mood disorders, changes in cognitive function or memory, sensory changes (numbness, pain, vibrations), motor changes (loss of balance, poor coordination, muscle weakness or stiffness), vision changes (double vision, blurred vision, loss of vision) and bladder or bowel dysfunction. Treatments are available that can help minimise some of these symptoms and relieve patient distress. After the diagnosis has been established and a decision taken regarding initiation of immunomodulatory treatments, the majority of management decisions with which the physician will be confronted will concern symptom management. Whereas some symptoms are relatively easily treated, others are more difficult to manage. Management involves rehabilitation, pharmacological treatments and surgical procedures. Successful symptom management is a key determinant of quality of life for the patient and is the basis for improving physical and psychological function.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rothwell PM
        • McDowell Z
        • Wong CK
        • Dorman PJ
        Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis.
        BMJ. 1997; 314: 1580-1583
        • Orme M
        • Kerrigan J
        • Tyas D
        • Russell N
        • Nixon R
        The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.
        Value Health. 2007; 10: 54-60
        • Simmons RD
        • Tribe KL
        • McDonald EA
        Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management.
        J Neurol. 2010; 257: 926-936
        • Amato MP
        • Ponziani G
        • Rossi F
        • Liedl CL
        • Stefanile C
        • Rossi L
        Quality of life in multiple sclerosis: the impact of depression, fatigue and disability.
        Mult Scler. 2001; 7: 340-344
        • Janardhan V
        • Bakshi R
        Quality of life in patients with multiple sclerosis: the impact of fatigue and depression.
        J Neurol Sci. 2002; 205: 51-58
        • D'Alisa S
        • Miscio G
        • Baudo S
        • Simone A
        • Tesio L
        • Mauro A
        Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study.
        Disabil Rehabil. 2006; 28: 307-314
        • Fruehwald S
        • Loeffler-Stastka H
        • Eher R
        • Saletu B
        • Baumhackl U
        Depression and quality of life in multiple sclerosis.
        Acta Neurol Scand. 2001; 104: 257-261
        • Kern S
        • Schrempf W
        • Schneider H
        • Schultheiss T
        • Reichmann H
        • Ziemssen T
        Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis.
        Mult Scler. 2009; 15: 752-758
        • Crayton H
        • Heyman RA
        • Rossman HS
        A multimodal approach to managing the symptoms of multiple sclerosis.
        Neurology. 2004; 63: S12-S18
        • Patten SB
        • Beck CA
        • Williams JV
        • Barbui C
        • Metz LM
        Major depression in multiple sclerosis: a population-based perspective.
        Neurology. 2003; 61: 1524-1527
        • Sadovnick AD
        • Remick RA
        • Allen J
        • et al.
        Depression and multiple sclerosis.
        Neurology. 1996; 46: 628-632
        • Chwastiak L
        • Ehde DM
        • Gibbons LE
        • Sullivan M
        • Bowen JD
        • Kraft GH
        Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.
        Am J Psychiatry. 2002; 159: 1862-1868
        • Ziemssen T
        Multiple sclerosis beyond EDSS: depression and fatigue.
        J Neurol Sci. 2009; 277: S37-S41
        • Lee D
        • Newell R
        • Ziegler L
        • Topping A
        Treatment of fatigue in multiple sclerosis: a systematic review of the literature.
        Int J Nurs Pract. 2008; 14: 81-93
        • Flachenecker P
        • Stuke K
        • Elias W
        • et al.
        Multiple sclerosis registry in Germany: results of the extension phase 2005/2006.
        Dtsch Arztebl Int. 2008; 105: 113-119
        • Cohen BA
        Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis.
        Neurology. 2008; 71: S14-S20
        • Greenhalgh J
        • Ford H
        • Long AF
        • Hurst K
        The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis.
        J Neurol Neurosurg Psychiatry. 2004; 75: 577-582
        • Beaumont JG
        The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis.
        J Neurol Neurosurg Psychiatry. 2004; 75: 526-527
        • Ziemssen T
        • Kratzsch F
        • Eulitz M
        • Kempcke R
        • Kleiner N
        Development and first evaluation of the new patient management and documentation system MSDS 3D for patients with multiple sclerosis.
        Neurology. 2010; 74: A554
        • Avasarala JR
        • Cross AH
        • Trinkaus K
        Comparative assessment of Yale Single Question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis.
        Mult Scler. 2003; 9: 307-310
        • Vahter L
        • Kreegipuu M
        • Talvik T
        • Gross-Paju K
        One question as a screening instrument for depression in people with multiple sclerosis.
        Clin Rehabil. 2007; 21: 460-464
        • Zorzon M
        • Zivadinov R
        • Bosco A
        • et al.
        Sexual dysfunction in multiple sclerosis: a case–control study. I. Frequency and comparison of groups.
        Mult Scler. 1999; 5: 418-427
        • Zorzon M
        • Zivadinov R
        • Monti Bragadin L
        • et al.
        Sexual dysfunction in multiple sclerosis: a 2-year follow-up study.
        J Neurol Sci. 2001; 187: 1-5
        • Chao CC
        • DeLaHunt M
        • Hu S
        • Close K
        • Peterson PK
        Immunologically mediated fatigue: a murine model.
        Clin Immunol Immunopathol. 1992; 64: 161-165
        • Kern S
        • Ziemssen T
        Brain-immune communication psychoneuroimmunology of multiple sclerosis.
        Mult Scler. 2008; 14: 6-21
        • Heesen C
        • Schulz H
        • Schmidt M
        • Gold S
        • Tessmer W
        • Schulz KH
        Endocrine and cytokine responses to acute psychological stress in multiple sclerosis.
        Brain Behav Immun. 2002; 16: 282-287
        • Dickinson CJ
        Chronic fatigue syndrome – aetiological aspects.
        Eur J Clin Invest. 1997; 27: 257-267
        • Djaldetti R
        • Ziv I
        • Achiron A
        • Melamed E
        Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment.
        Neurology. 1996; 46: 632-635
        • Roelcke U
        • Kappos L
        • Lechner-Scott J
        • et al.
        Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study.
        Neurology. 1997; 48: 1566-1571
        • Miller DH
        Demyelinating, inflammatory and degenerative diseases.
        Curr Opin Neurol Neurosurg. 1990; 3: 881-883
        • Kent-Braun JA
        • Sharma KR
        • Miller RG
        • Weiner MW
        Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis.
        Muscle Nerve. 1994; 17: 835-841
        • Metz LM
        • Patten SB
        • Archibald CJ
        • et al.
        The effect of immunomodulatory treatment on multiple sclerosis fatigue.
        J Neurol Neurosurg Psychiatry. 2004; 75: 1045-1047
        • Ziemssen T
        • Hoffman J
        • Apfel R
        • Kern S
        Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing–remitting multiple sclerosis.
        Health Qual Life Outcomes. 2008; 6: 67
        • Henze T
        • Rieckmann P
        • Toyka KV
        Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.
        Eur Neurol. 2006; 56: 78-105
        • Mohr DC
        • Goodkin DE
        • Likosky W
        • Gatto N
        • Baumann KA
        • Rudick RA
        Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.
        Arch Neurol. 1997; 54: 531-533
        • Mohr DC
        • Hart SL
        • Fonareva I
        • Tasch ES
        Treatment of depression for patients with multiple sclerosis in neurology clinics.
        Mult Scler. 2006; 12: 204-208
        • Wade DT
        • Collin C
        • Stott C
        • Duncombe P
        Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
        Mult Scler. 2010; 16: 707-714
        • Goodman AD
        • Brown TR
        • Krupp LB
        • et al.
        Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
        Lancet. 2009; 373: 732-738
        • Dalgas U
        Rehabilitation and multiple sclerosis: hot topics in the preservation of physical functioning.
        J Neurol Sci. 2011; 311: S43-S47